VivoSeq
Other

Familial Chylomicronemia Syndrome

0

Pipeline Programs↗

3

Active Trials↗

5

Companies Involved↗

Familial Chylomicronemia Syndrome is an early-stage landscape with 0 programs across 5 companies. The most active players are Ionis Pharmaceuticals, Akcea Therapeutics, Arrowhead Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ionis Pharmaceuticals logo

Ionis Pharmaceuticals

0 programs

PreclinicalA

Akcea Therapeutics

0 programs

PreclinicalArrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalV

Visirna Therapeutics HK Limited

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Completed7 · 54%
Active, not recruiting3 · 23%
Terminated1 · 8%
Approved for marketing1 · 8%
No longer available1 · 8%

Clinical Trials

Trial Activity

13 trials

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen
Active, not recruiting·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 3·NCT05185843·24 enrolled
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
Active, not recruiting·Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals·Phase 3·NCT05089084·75 enrolled
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
Active, not recruiting·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 3·NCT05130450·60 enrolled
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
Completed·Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals·Phase 1·NCT03783377·112 enrolled
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 3·NCT04568434·66 enrolled
Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)
Completed·AAkcea Therapeutics·Phase 2·NCT03360747·3 enrolled
The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome
Completed·Ionis Pharmaceuticals logoIonis Pharmaceuticals·Phase 3·NCT02211209·67 enrolled
A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome
Completed·VVisirna Therapeutics HK Limited·Phase 3·NCT05902598·37 enrolled
The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome
Completed·AAkcea Therapeutics·Phase 3·NCT02658175·68 enrolled
A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome
Completed·Novartis logoNovartis·Phase 3·NCT01514461·45 enrolled
Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.
Terminated·Novartis logoNovartis·Phase 3·NCT01589237·38 enrolled
Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
Approved for marketing·Ionis Pharmaceuticals logoIonis Pharmaceuticals·N/A·NCT06360237
Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
No longer available·AAkcea Therapeutics·N/A·NCT03544060

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)